Post date
12/12/2019
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Gosselies, Belgium and Cambridge, MA – Dec. 12, 2019 – iTeos
Post date
14/11/2019
- Bringing Innovative Liver-Focused Cell therapies to Japanese Markets -
Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have
Post date
05/12/2019
Belgium – 5 November 2019 – Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced
Post date
02/10/2019
Study highlights potential benefit in rare pediatric orthopedic disorder
Mont-Saint-Guibert, Belgium, October 2, 2019 : Novadip Biosciences (“Novadip” or “the company”), a clinical-stage
Post date
13/09/2019
GO plc in Malta has launched a converged fixed and mobile solution using Tessares’s Multipath TCP technology. Available to all GO plc customers, this solution combines the operator's fixed
Post date
09/01/2019
After a first order of its flagship product - the best dry ginseng in the world - in May 2018, Pierre-Antoine Mariage and Paul-Evence Coppée are expanding internationally thanks to important contracts
Post date
20/06/2018
VIVES, a long-standing investor in iTeos Therapeutics, participated in the Series B €64 million fundraise. The lead and new investor, the American fund MPM Capital, will allow the UCLouvain spin-off
Post date
27/04/2018
A-Mansia Biotech S.A. is active in the microbiome field based on pioneering research on Akkermansia muciniphila (A. muciniphila) from two well-known scientists, Prof. P. Cani (Université catholique de
Post date
22/03/2018
Proximus and VIVES II, existing shareholders of Tessares, are thereby strengthening their participation and are joined by the SRIW which is also participating. The amount raised is aimed at speeding
Post date
05/02/2018
- Syndesi Therapeutics to leverage UCB’s expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism
- Series A financing of €17 M from
Post date
26/06/2017
Louvain-la-Neuve, 26th June 2017 - Aphea.Bio, spin-off of the VIB, UGent and KU Leuven, will develop sustainable agricultural products based on nature-based microorganisms to increase crop yield and